EP2825989A4 - Verfahren zur verteilung von komplementhemmenden medikamenten an komplementhemmer empfangende patienten - Google Patents

Verfahren zur verteilung von komplementhemmenden medikamenten an komplementhemmer empfangende patienten

Info

Publication number
EP2825989A4
EP2825989A4 EP12870989.6A EP12870989A EP2825989A4 EP 2825989 A4 EP2825989 A4 EP 2825989A4 EP 12870989 A EP12870989 A EP 12870989A EP 2825989 A4 EP2825989 A4 EP 2825989A4
Authority
EP
European Patent Office
Prior art keywords
complement
methods
distributing
patients receiving
inhibiting drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP12870989.6A
Other languages
English (en)
French (fr)
Other versions
EP2825989A2 (de
Inventor
Leonard Bell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of EP2825989A2 publication Critical patent/EP2825989A2/de
Publication of EP2825989A4 publication Critical patent/EP2825989A4/de
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00—Control; Monitoring or safety arrangements
    • F04C2270/04—Force
    • F04C2270/041—Controlled or regulated
EP12870989.6A 2012-03-16 2012-03-16 Verfahren zur verteilung von komplementhemmenden medikamenten an komplementhemmer empfangende patienten Ceased EP2825989A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/029499 WO2013137912A2 (en) 2012-03-16 2012-03-16 Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor

Publications (2)

Publication Number Publication Date
EP2825989A2 EP2825989A2 (de) 2015-01-21
EP2825989A4 true EP2825989A4 (de) 2016-01-06

Family

ID=49161929

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12870989.6A Ceased EP2825989A4 (de) 2012-03-16 2012-03-16 Verfahren zur verteilung von komplementhemmenden medikamenten an komplementhemmer empfangende patienten

Country Status (6)

Country Link
EP (1) EP2825989A4 (de)
CN (1) CN104205155A (de)
EA (1) EA201400950A1 (de)
HK (1) HK1204693A1 (de)
IL (1) IL234680A0 (de)
WO (1) WO2013137912A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010837A8 (pt) 2013-11-13 2020-04-22 Shire Viropharma Inc uso de uma composição compreendendo um inibidor de c1-esterase (c1-inh), composição farmacêutica compreendendo o mesmo e seus kits
CN105260974A (zh) * 2015-09-10 2016-01-20 济南市儿童医院 一种生成具有告签功能的电子病历方法及系统
CN115177291B (zh) * 2022-08-01 2023-11-10 首都医科大学附属北京朝阳医院 用于识别重症监护病房获得性肌无力的方法和装置

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US20040117126A1 (en) * 2002-11-25 2004-06-17 Fetterman Jeffrey E. Method of assessing and managing risks associated with a pharmaceutical product
WO2006034367A2 (en) * 2004-09-20 2006-03-30 University Of Florida Research Foundation, Inc. Methods and systems for preventing diversion of prescription drugs
EP1720571A2 (de) * 2004-02-03 2006-11-15 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung einer hämolytischen erkrankung
US20080097784A1 (en) * 2006-07-17 2008-04-24 Walgreen Co. Appropriateness Of A Medication Therapy Regimen
EP2359834A1 (de) * 2006-03-15 2011-08-24 Alexion Pharmaceuticals, Inc. Hemmer des Komplements zur Behandlung der paroxysmalen nächtlichen Haemoglobinurie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2053961A4 (de) * 2006-08-09 2013-05-01 Biogen Idec Inc Verfahren zur verbreitung eines wirkstoffs
CA3035432A1 (en) * 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2011091078A2 (en) * 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US20040117126A1 (en) * 2002-11-25 2004-06-17 Fetterman Jeffrey E. Method of assessing and managing risks associated with a pharmaceutical product
EP1720571A2 (de) * 2004-02-03 2006-11-15 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung einer hämolytischen erkrankung
WO2006034367A2 (en) * 2004-09-20 2006-03-30 University Of Florida Research Foundation, Inc. Methods and systems for preventing diversion of prescription drugs
EP2359834A1 (de) * 2006-03-15 2011-08-24 Alexion Pharmaceuticals, Inc. Hemmer des Komplements zur Behandlung der paroxysmalen nächtlichen Haemoglobinurie
US20080097784A1 (en) * 2006-07-17 2008-04-24 Walgreen Co. Appropriateness Of A Medication Therapy Regimen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HILL ANITA ET AL: "Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 106, no. 7, 1 October 2005 (2005-10-01), pages 2559 - 2565, XP002482089, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2005-02-0564 *
R. A. BRODSKY ET AL: "Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria", BLOOD, vol. 111, no. 4, 30 November 2007 (2007-11-30), US, pages 1840 - 1847, XP055228630, ISSN: 0006-4971, DOI: 10.1182/blood-2007-06-094136 *
ROTHER R P ET AL: "Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, US, vol. 25, no. 11, 12 December 2007 (2007-12-12), pages 1256 - 1264, XP002553743, ISSN: 1087-0156, [retrieved on 20071107], DOI: 10.1038/NBT1344 *

Also Published As

Publication number Publication date
WO2013137912A2 (en) 2013-09-19
EA201400950A1 (ru) 2014-12-30
HK1204693A1 (en) 2015-11-27
EP2825989A2 (de) 2015-01-21
IL234680A0 (en) 2014-11-30
CN104205155A (zh) 2014-12-10
WO2013137912A3 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
HK1205697A1 (en) Prodrugs of hydroxyl-comprising drugs
HK1198132A1 (en) Tamper-resistant tablet providing immediate drug release
HK1198131A1 (en) Tamper-resistant tablet providing immediate drug release
ZA201307862B (en) Controlled release pharmaceutical dosage forms
IL238713A0 (en) Self-regulating active pharmaceutical ingredient release
HK1206937A1 (en) Methods of administering pirfenidone therapy
PT3415139T (pt) Administração de benzodiazepina
EP2864361A4 (de) Dosierungsschema für fusionsverbindungen
HK1206292A1 (en) Medicament administration
ZA201405797B (en) Pharmaceutical dosage form
AP2015008208A0 (en) Pharmaceutical administration forms comprising
PL2890777T3 (pl) Kompozycja farmaceutyczna zawierająca pcmv-vegf165 do stymulacji angiogenezy
EP2898912A4 (de) Instrument zur arzneimittelverabreichung
HK1204693A1 (en) Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
AP2014007760A0 (en) Stabilized pharmaceutical formulations of a potentHCV inhibitor
ZA201502354B (en) Pharmaceutical dosage form
IL237221A0 (en) Analogues of phospholipid drugs
GB201104632D0 (en) Use of medicament
GB201213729D0 (en) Manufacture of insoluble drugs
GB201113172D0 (en) Medical blister

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141014

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1204693

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20151207

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20151201BHEP

Ipc: C07K 16/18 20060101ALI20151201BHEP

Ipc: G06F 19/00 20110101AFI20151201BHEP

Ipc: G06F 19/28 20110101ALI20151201BHEP

Ipc: A61K 31/00 20060101ALI20151201BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180413

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20191031

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1204693

Country of ref document: HK